Literature DB >> 23908484

Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers.

James S McCarthy1, Paul M Griffin, Silvana Sekuloski, A Taylor Bright, Rebecca Rockett, David Looke, Suzanne Elliott, David Whiley, Theo Sloots, Elizabeth A Winzeler, Katharine R Trenholme.   

Abstract

BACKGROUND: Major impediments to development of vaccines and drugs for Plasmodium vivax malaria are the inability to culture this species and the extreme difficulty in undertaking clinical research by experimental infection.
METHODS: A parasite bank was collected from a 49-year-old woman with P. vivax infection, characterized, and used in an experimental infection study.
RESULTS: The donor made a full recovery from malaria after collection of a parasite bank, which tested negative for agents screened for in blood donations. DNA sequence analysis of the isolate indicated that it was clonal. Two subjects inoculated with the isolate became polymerase chain reaction positive on days 8 and 9, with onset of symptoms and positive blood smears on day 14, when they were treated with artemether-lumefantrine, with rapid clinical and parasitologic response. Transcripts of the parasite gene pvs25 that is expressed in gametocytes, the life cycle stage infectious to mosquitoes, were first detected on days 11 and 12.
CONCLUSIONS: This experimental system results in in vivo parasite growth, probably infectious to mosquitoes. It offers the opportunity to undertake studies previously impossible in P. vivax that will facilitate a better understanding of the pathology of vivax malaria and development of antimalarial drugs and vaccines. Trial Registration. ANZCTR: 12612001096842.

Entities:  

Keywords:  Plasmodium vivax; experimental infection; malaria

Mesh:

Year:  2013        PMID: 23908484      PMCID: PMC3888148          DOI: 10.1093/infdis/jit394

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum.

Authors:  M B Reed; K J Saliba; S R Caruana; K Kirk; A F Cowman
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

2.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Authors:  James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

3.  Fluorescent antibody studies on the immune response in sporozoite-induced and blood-induced vivax malaria and the relationship of antibody production to parasitemia.

Authors:  J E Tobie; D C Abele; G J Hill; P G Contacos; C B Evans
Journal:  Am J Trop Med Hyg       Date:  1966-09       Impact factor: 2.345

4.  Mefloquine (WR 142,490) in the treatment of human malaria.

Authors:  C M Trenholme; R L Williams; R E Desjardins; H Frischer; P E Carson; K H Rieckmann; C J Canfield
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

5.  Human challenge studies with infectious agents.

Authors:  Karen L Kotloff
Journal:  J Investig Med       Date:  2003-02       Impact factor: 2.895

Review 6.  Malariotherapy--insanity at the service of malariology.

Authors:  Georges Snounou; Jean-Louis Pérignon
Journal:  Adv Parasitol       Date:  2013       Impact factor: 3.870

7.  Multiple transporters associated with malaria parasite responses to chloroquine and quinine.

Authors:  Jianbing Mu; Michael T Ferdig; Xiaorong Feng; Deirdre A Joy; Junhui Duan; Tetsuya Furuya; G Subramanian; L Aravind; Roland A Cooper; John C Wootton; Momiao Xiong; Xin-zhuan Su
Journal:  Mol Microbiol       Date:  2003-08       Impact factor: 3.501

8.  Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine.

Authors:  Michele D Hastings; Kathryn M Porter; Jason D Maguire; Ika Susanti; Winni Kania; Michael J Bangs; Carol Hopkins Sibley; J Kevin Baird
Journal:  J Infect Dis       Date:  2004-02-04       Impact factor: 5.226

9.  Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site.

Authors:  Michael Korsinczky; Katja Fischer; Nanhua Chen; Joanne Baker; Karl Rieckmann; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax.

Authors:  William E Collins; Geoffrey M Jeffery; Jacquelin M Roberts
Journal:  Am J Trop Med Hyg       Date:  2004-06       Impact factor: 2.345

View more
  48 in total

Review 1.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

2.  Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation.

Authors:  Tonia Woodberry; Jessica R Loughland; Gabriela Minigo; Julie G Burel; Fiona H Amante; Kim A Piera; Yvette McNeil; Tsin W Yeo; Michael F Good; Denise L Doolan; Christian R Engwerda; James S McCarthy; Nicholas M Anstey
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

3.  Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.

Authors:  Stephan Karl; Moses Laman; Brioni R Moore; John Benjamin; Tamarah Koleala; Clemencia Ibam; Bernadine Kasian; Peter M Siba; Andreea Waltmann; Ivo Mueller; Robert C Woodward; Timothy G St Pierre; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

4.  Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite.

Authors:  Danielle I Stanisic; John Gerrard; James Fink; Paul M Griffin; Xue Q Liu; Lana Sundac; Silvana Sekuloski; Ingrid B Rodriguez; Jolien Pingnet; Yuedong Yang; Yaoqi Zhou; Katharine R Trenholme; Claire Y T Wang; Hazel Hackett; Jo-Anne A Chan; Christine Langer; Eric Hanssen; Stephen L Hoffman; James G Beeson; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

Review 5.  Malaria modeling: In vitro stem cells vs in vivo models.

Authors:  Florian Noulin
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

Review 6.  Safety Considerations for Malaria Volunteer Infection Studies: A Mini-Review.

Authors:  Anand Odedra; James S McCarthy
Journal:  Am J Trop Med Hyg       Date:  2020-05       Impact factor: 2.345

7.  Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial.

Authors:  Nicholas M Anstey; Tsin W Yeo; Matthew J Grigg; Timothy William; Jayaram Menon; Prabakaran Dhanaraj; Bridget E Barber; Christopher S Wilkes; Lorenz von Seidlein; Giri S Rajahram; Cielo Pasay; James S McCarthy; Ric N Price
Journal:  Lancet Infect Dis       Date:  2015-11-19       Impact factor: 25.071

8.  Human Plasmodium vivax mosquito experimental transmission.

Authors:  David J Sullivan; Peter Agre
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 9.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

10.  Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.

Authors:  Ruth O Payne; Kathryn H Milne; Sean C Elias; Nick J Edwards; Alexander D Douglas; Rebecca E Brown; Sarah E Silk; Sumi Biswas; Kazutoyo Miura; Rachel Roberts; Thomas W Rampling; Navin Venkatraman; Susanne H Hodgson; Geneviève M Labbé; Fenella D Halstead; Ian D Poulton; Fay L Nugent; Hans de Graaf; Priya Sukhtankar; Nicola C Williams; Christian F Ockenhouse; April K Kathcart; Aziz N Qabar; Norman C Waters; Lorraine A Soisson; Ashley J Birkett; Graham S Cooke; Saul N Faust; Colleen Woods; Karen Ivinson; James S McCarthy; Carter L Diggs; Johan Vekemans; Carole A Long; Adrian V S Hill; Alison M Lawrie; Sheetij Dutta; Simon J Draper
Journal:  J Infect Dis       Date:  2016-02-04       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.